2019
DOI: 10.3390/cancers11030390
|View full text |Cite
|
Sign up to set email alerts
|

Personalized Radiation Therapy in Cancer Pain Management

Abstract: The majority of advanced cancer patients suffer from pain, which severely deteriorates their quality of life. Apart from analgesics, bisphosphonates, and invasive methods of analgesic treatment (e.g., intraspinal and epidural analgesics or neurolytic blockades), radiation therapy plays an important role in pain alleviation. It is delivered to a growing primary tumour, lymph nodes, or distant metastatic sites, producing pain of various intensity. Currently, different regiments of radiation therapy methods and t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
7
0
1

Year Published

2019
2019
2023
2023

Publication Types

Select...
8
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 19 publications
(8 citation statements)
references
References 150 publications
(212 reference statements)
0
7
0
1
Order By: Relevance
“…Bone-seeking radiopharmaceuticals have been employed as active osteotropic approaches [83], representing calcium mimetics in the bone compartement, which emit alpha, beta, and gamma particles. Strontium-89 chloride, Samarium-153-ethylenediamine tetramethylene phosphonic acid (EDTMP), Rhenium-186-hydroxyethylidine diphosphonic acid (HEDP), and Radium-233 dichloride were indicated for the treatment of painful lesions due to osteoblastic or mixed bone metastases, mainly from breast and prostate tumors and other cancers with osteoblastic skeletal spreading, detected by whole-body bone scans performed ahead of treatment [83]. These compounds mainly target osteoblastic skeletal lesions, however, they are not effective on lytic bone lesions, increasing the fracture incidence [84].…”
Section: Clinical Management For Skeletal Metastasis Of Unknown Prmentioning
confidence: 99%
“…Bone-seeking radiopharmaceuticals have been employed as active osteotropic approaches [83], representing calcium mimetics in the bone compartement, which emit alpha, beta, and gamma particles. Strontium-89 chloride, Samarium-153-ethylenediamine tetramethylene phosphonic acid (EDTMP), Rhenium-186-hydroxyethylidine diphosphonic acid (HEDP), and Radium-233 dichloride were indicated for the treatment of painful lesions due to osteoblastic or mixed bone metastases, mainly from breast and prostate tumors and other cancers with osteoblastic skeletal spreading, detected by whole-body bone scans performed ahead of treatment [83]. These compounds mainly target osteoblastic skeletal lesions, however, they are not effective on lytic bone lesions, increasing the fracture incidence [84].…”
Section: Clinical Management For Skeletal Metastasis Of Unknown Prmentioning
confidence: 99%
“…Tumor cells then release cytokines that aim to further stimulate osteoclasts and, in consequence, bone resorption. Novel literature delivers evidence that radiation treatment not only acts on OCs and OBs, but also changes the bone microenvironment, including by reduction of inflammatory cells and chemical pain mediators which, in turn, results in cancer-induced pain relief [ 262 , 263 , 264 ] ( Figure 4 ).…”
Section: Radiotherapymentioning
confidence: 99%
“…Если целью лечения является облегчение боли, то в качестве стандартного фракционирования дозы для симптоматических и неосложненных метастазов в кости рекомендуется однократная доза в 8 Гр, назначенная до соответствующего целевого объема. Однако общая доза 30 Гр за 10 фракций также считается стандартным методом с более низкой частотой патологических переломов и компрессии спинного мозга [37]. Относительно химиотерапии, за исключением внутривенного введения, паллиативная транскатетерная артериальная химиоэмболизация/эмболизация может быть подходящим методом симптоматического лечения метастазов в кости, поскольку он является минимально инвазивным, повторяемым, эффективным и быстродействующим [38].…”
Section: метастатический рак шейки матки в костиunclassified